My New Video Update and Commentary for Past Week, and Week Ahead 8/5/2013 $TSRX, $ONTX, $CBST, $ATRS, $BIOD, $FB
Author: Scott Matusow
Trade Alert: $ASTX Pharma Target $5.75 to $6
Trade Alert: $ASTX Pharma Target $5.75 to $6 Reason = Cup and handle continuation, earnings out of way and upcoming catalyst. We can see the cup and handle continuation above, with accumulation turning up, and RSI turning up. Money Flow…
Biodel Video Chart Analysis
My Biodel Chart Analysis Video – StockMatusow.com ‘s price target opinion for this catalyst run-up trade is around $6
Biodel Expecting To Release Top-Line Data Soon
Biodel (BIOD) is expecting top-line Phase II data for BIOD-123 to be released in the third quarter 2013. With the market for these products estimated to be about $10 billion in value, good results for Biodel’s product would be a…
Trade Call Alert: $FST, Short TermTarget = $5.75, Mid-Term, $7
Trade Call Alert: $FST, Target = $5.75, mid term $7. Reasons = Heavy call open interest verses puts, cup and handle continuation. C&A points to a move near $7, confirmed by the call interest verses the put side on the…
Market Commentary And Chart Analysis For Week July 29, 2013
$ATRS, $GTXI, $ASTX, $TSRX, $KERX, and others, plus macro and market commentary, and outlook for the upcoming trading for the week of July, 29th, 2013.
S&P 500 Bearish Head And Shoulders Forming – 10 Day Chart
Below, is what I have been referring to the last week or so in my videos; The market seems very topped out right now, and a lot of biotechs have runs very far, very fast. While it’s possible for us…
Significant Near Term Catalyst Should Further Rally Keryx Pharmaceuticals
Recently, we have detailed companies that have released positive Phase III data because we believe several of these companies continue to be under speculation value. Companies who have strong management, cash, and a strong pipeline can be very profitable for…
Trade and Catalyst Pick: $KERX My short term target opinion, $9.05
Trade and Catalyst Pick: $KERX My short term trade target opinion, $9.05, Catalyst run-up target, $9.50 – $10 KERX has a Phase II Chronic Kidney Disease (CKD) data release in the 3Q. Commenting on the quarter, Ron Bentsur, the Company’s…
Market Commentary And Chart Analysis For Week July 22, 2013
$ATRS, $GTXI, $ASTX, $TSRX, $KERX, plus macro and market commentary, and outlook for the upcoming trading week.
